Abstract
Alzheimer’s disease is an age-related neurodegenerative disorder that leads to cognitive and functional decline. Potential target proteins for managing Alzheimer’s disease include Acetylcholinesterase (AChE), Butyrylcholinesterase (BuChE), Beta-secretase cleavage enzyme (BACE1) and N-methyl-D-aspartate (NMDA) receptors. In this study, we conducted in silico evaluations of the inhibitory effects of Salvia miltiorrhiza’s compounds on AChE, BuChE, BACE1, and NMDA receptors. The Lipinski's rule of five was employed to compare phytochemicals with drug-like and non-drug-like properties. Based on previous publications, we compiled a list of 30 compounds from S.miltiorrhiza with potential for improving Alzheimer’s disease. Among these 30 compounds, six natural compounds exhibited potential inhibition of all four target proteins. Five of these six compounds, namely Tanshinone I, Tanshinone IIA, Isotanshinone I, Dihydroisotanshinone I, and Dihydroisotanshinone II, possessed drug-like properties, good absorption potential, and the ability to cross the blood-brain barrier. In conclusion, these five compounds show the highest potential as future drug candidates for the treatment of Alzheimer’s disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.